Effectiveness of combining plasma exchange and continuous hemodiafiltration (combined modality therapy in a parallel circuit) in the treatment of patients with acute hepatic failure

Therapeutic Apheresis

Volumn 5, Issue 6, 2001, Pages 471-475

  Nakae, Hajime ^a   Yonekawa, Chikara ^a   Wada, Hiroshi ^a   Asanuma, Yoshihiro ^a   Sato, Tsutomu ^a   Tanaka, Hiroyuki ^a  

^a AKITA UNIVERSITY   (Japan)

Author keywords

Acute hepatic failure; Citrate; Continuous hemodiafiltration; Plasma exchange; Proinflammatory cytokine

Indexed keywords

BILIRUBIN; CITRIC ACID; CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HUMAN; LIVER FAILURE; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

CITRATES; COMBINED MODALITY THERAPY; FEMALE; HEMODIAFILTRATION; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIVER FAILURE, ACUTE; MALE; MIDDLE AGED; PLASMA EXCHANGE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035677598     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2001.00380.x     Document Type: Article

References (13)

1. Changes in tumor necrosis factor-a and interleukin-1b production following liver surgery on cirrhotic patients
2. Are proinflammatory cytokine concentrations reduced by plasma exchange in patients with severe acute hepatic failure?
3. Combination of plasma exchange and continuous hemofiltration as temporary metabolic support for patients with acute liver failure
4. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure
5. Complications of plasma exchange
6. Citrate intoxication
7. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure
8. Effectiveness of the combination of plasma exchange and continuous hemodiafiltration in patients with acute hepatic failure
9. Continuous removal of middle molecules by hemofiltration in patients with acute liver failure
10. Circulating proinflammatory cytokines (IL-1β, TNF-α, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis
11. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
12. Plasma exchange and the arterial blood ketone body ratio in patients with acute hepatic failure
13. Continuous haemodiafiltration during and after cardiopulmonary bypass in renal failure patients